HNSA — Hansa Biopharma AB Share News
0.000.00%
Last trade - 00:00- SEK4.77bn
- SEK4.38bn
- SEK222.27m
Brief: Hansa Biopharma Total Q2 Revenue Of SEK 36.7 Mln
Brief: Hansa Biopharma Idefirix Receives Provisional Approval In Australia
Brief: Hansa Biopharma Recognizes Write-Up Of SEK 1.430 Bln Related To Idefirix
Brief: Hansa Biopharma Announces Positive Reimbursement Decision For Idefirix
Brief: Hansa Biopharma, Genethon Announce Collaboration To Develop Imlifidase As Pre-Treatment To Gene Therapy In Crigler-Najjar Syndrome Patients With Anti-AAV Antibodies
Brief: Hansa Biopharma And Genethon Announce Collaboration To Develop Imlifidase AS Pre-Treatment To Gene Therapy
Brief: Hansa Biopharma Interim Report January-March 2023
Brief: Hansa Biopharma Total Q1 Revenue Of SEK 24.2 Mln
Brief: Hansa Biopharma Announces Positive Reimbursement Decision In Spain For Idefirix As Desensitization Treatment
Brief: Hansa Biopharma Announces Positive Reimbursement Decision In Spain For Idefirix
Brief: Hansa Biopharma Q4 Operating Loss Narrows To SEK 144.7 Mln
Brief: Hansa Biopharma Gets Reimbursement For Idefirix In Czech Republic
Brief: Hansa Biopharma Announces Successful Execution Of A Directed Share Issue Of SEK 416 Million (~USD 40 Million)
Brief: Hansa Biopharma Announces Positive Reimbursement Decision For Idefirix In Italy
Brief: Hansa Biopharma Announces Positive Topline Data From Imlifidase Phase 2 Study
Brief: Hansa Biopharma And Partner Sarepta Therapeutics Plan To Initiate A Clinical Study With Imlifidase As A Pre-Treatment To Sarepta's SRP-9001 Gene Therapy In DMD In 2023
Brief: Hansa And Sarepta Therapeutics To Initiate Clinical Study With Imlifidase As A Pre-Treatment To Sarepta's Srp-9001 Gene Therapy In Dmd In 2023
Brief: Hansa Biopharma Revenue Of SEK 67 Mln In Q3 2022
Brief: The Scottish Medicines Consortium Recommends Use Of Hansa Biopharma's Idefirix As Desensitization Treatment For Highly Sensitized Kidney Transplant Patients